Author: Pradip Tikhe

The U.S. government’s “Project Nextgen,” its effort to accelerate and streamline the rapid development of the next generation of Covid vaccines and treatments, said Wednesday that it would give a small biotechnology firm, Gritstone bio, up to $433 million to conduct a 10,000-volunteer clinical trial testing a new approach to creating a vaccine. The deal highlights the possibility of developing a new approach to Covid shots. But the huge amount of money and large number of study subjects involved also show the challenges inherent in improving on the vaccines already manufactured by Moderna as well as by Pfizer and its…

Read More

The company has a good repute in the fermentation-based API segment. A number of fermentation-based biologic drugs are expected to lose exclusivity in the next two years, and this opens a $60 billion opportunity. Highlights: Focus on immunosuppressants & oncology fermentation APIs Significant barriers to entry due to the resources & skill set needed Near-term watch are plans for formulations & injectables Successful USFDA inspection of API & formulation plants Investors can consider stock for a longer term horizon Concord Biotech (CMP: Rs 1,001; Market cap: Rs 10,472 crore) has had a smart entry into the secondary market, with…

Read More

The longevity biotech industry revolves around the goal of increasing the period of life that a person spends in good health. There has been a rapidly expanding effort in recent years to develop drugs that target aging as a root cause of disease, and this type of biotechnology has come to be a very popular focus for many companies, leading to numerous anti-aging biotech startups popping up around the world. The primary technology used when developing anti-aging therapies is epigenetic reprogramming, which involves the identification of specific sets of transcription factors that can induce changes in gene expression and cellular…

Read More

ADOBE This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround. The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and…

Read More

Bora Health, a global design, development and distribution partner of pharmaceuticals and health foods and part of the Bora group, has announced its collaboration with Sunway Biotech, a leading ingredients manufacturer, and research and development (R&D) organisation. Resulting in the parent company of Bora Health, Bora Pharmaceuticals becoming the largest shareholder of Sunway Biotech. Sunway Biotech gives the Bora Group access to a full suite of fermentation and extraction facilities with full R&D and analytical capabilities. Bora’s CDMO business will be able to use Sunway’s yeast manufacturing technology at its facility in Taipei, Taiwan to produce Ankascin 568-R, an ingredient used for the formulation of…

Read More

No one likes to be reminded that their largest organ is a veritable menagerie of microbes. But Parallel Health turns the skin microbiome from creepy fact to potentially transformative skin care by engineering a custom cocktail of phages and siccing them on the bacteria that cause acne and other conditions. Parallel Health emerged from stealth today at TechCrunch Disrupt as part of the Startup Battlefield, revealing (beyond their existence) $2.3 million in pre-seed funding and a first product, a custom phage therapy skin serum. The company got its start out of a project at a larger cosmetics company, where they were attempting to…

Read More

Portage is a clinical-stage immuno-oncology company advancing multi-targeted therapies to extend survival and significantly improve the lives of patients with cancer. Lead programs in the Portage portfolio include first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. These programs are being advanced using innovative trial designs and translational data to identify the patient populations most likely to benefit from treatment. The Company’s unique business model leverages a strong network of academic experts and large pharma partners to rapidly and efficiently advance multiple products. For more information.

Read More

The Rice Biotech Launch Pad accelerator was announced on the 61st anniversary of President John F. Kennedy’s moonshot speech. This initiative aims to develop new research and emerging technologies into practical clinical applications by bridging the gap between researchers, medical companies and healthcare professionals, Omid Veiseh said. Omid Veiseh, an associate professor in the department of bioengineering and a biotechnologies entrepreneur, serves as the faculty director of the Launch Pad. Veiseh said the Launch Pad will support new discoveries through navigating regulatory procedures, manufacturing and business development. “Our vision for this launch pad is to create the necessary infrastructure ……

Read More

1. Philanthropic disease foundations rival VCs in life sciences The third in the Business Journal’s three-part series on philanthropy and business focuses on disease foundations and venture capital. Nonprofit investors maintain that despite their similarities to venture capital firms, the model also has drawbacks, including misaligned incentives, reports Rowan Walrath. Scroll down for more. 2. At last: A biotech IPO Rowan also reports on a rarity for 2023: A biotech company just went public in a $250 million IPO, at a $2.7 billion valuation. 3. Cambridge Health Alliance to require masks starting today Cassie McGrath reports that Cambridge Health Alliance has reinstated its mask mandate for…

Read More

Biotech startup Generate Biomedicines, which uses artificial intelligence to find new drugs, raised $273 million in a Series C funding round from investors including pharma company Amgen and the VC arm of AI giant NVIDIA. Generate was founded in 2018 by venture-creation firm Flagship Pioneering to use machine learning algorithms to identify antibodies, peptides, cell therapies, and other medicines. It launched its first clinical trial in July for a Covid monoclonal antibody, and is working on starting another clinical trial for an asthma treatment. The biotech, which is based in Somerville, Mass., has big plans for the next couple of…

Read More